Can MRGPRX2 inhibition prevent migraine? Evommune’s EVO756 enters Phase 2b study
Evommune begins a Phase 2b EVO756 migraine trial after a urticaria setback, testing whether MRGPRX2 inhibition can deliver preventive benefit.
Pharma & Biotech
Pharma & Biotech
LAPIX Therapeutics adds biotech dealmaking expertise as LPX-TI641 studies progress
LAPIX adds Nimbus CEO Abbas Kazimi to its board as LPX-TI641 advances in Phase 1b autoimmune trials and prepares for Phase 2 decisions.
Pharma & Biotech
Could BBT001 quarterly dosing differentiate Bambusa in the atopic dermatitis biologics market?
Bambusa’s BBT001 produced an early atopic dermatitis signal, but larger trials must confirm safety, durability and quarterly dosing.
Medical Devices & Diagnostics
Castle Biosciences wins crucial New York access, but can AdvanceAD-Tx overcome the reimbursement test?
Castle Biosciences gains New York approval for AdvanceAD-Tx, expanding access while reimbursement and clinical adoption remain decisive.
Pharma & Biotech
LEO Pharma reports long-term pediatric tralokinumab safety findings from TRAPEDS-1
LEO Pharma’s TRAPEDS-1 data support pediatric tralokinumab development, but the small trial leaves efficacy and approval questions open.
Pharma & Biotech
Could Arcutis Biotherapeutics unlock the next big pediatric dermatology gap with Zoryve?
Arcutis Biotherapeutics has secured U.S. Food and Drug Administration acceptance of its supplemental New Drug Application for Zoryve roflumilast cream 0.05 percent to expand treatment of mild to moderate atopic dermatitis to infants aged 3 to 24 months. The filing moves the steroid-free topical therapy into a regulatory review with a target action date of
Pharma & Biotech
Turn Therapeutics moves to refine GX-03 as the atopic dermatitis evidence bar rises
Explore how Turn Therapeutics is refining the GX-03 Phase 2 trial after rapid eczema responses and a strong vehicle effect. Read what comes next.
Pharma & Biotech
Incyte’s Opzelura wins positive CHMP opinion for moderate atopic dermatitis in Europe
The positive opinion moves ruxolitinib cream closer to a broader European label for adults inadequately controlled by standard topical therapies, opening a potential treatment position between conventional creams and systemic medicines.
Features & Analysis
How EBGLYSS shows the eczema market is moving from breakthrough launches to lifecycle strategy
Find out why fewer injections and longer disease control are becoming key battlegrounds in eczema biologics and dermatology care.
Pharma & Biotech
Why Lilly’s expanded Ebglyss label could reset dosing expectations in atopic dermatitis biologics
Ebglyss gains an every-eight-week FDA maintenance option, raising new questions for atopic dermatitis biologic competition.